Search research articles
Contact Us
Filters
Showing results (1-10 of 61) with videos related to
Page
of 7
Sort By:
Expert Opinion on Biological Therapy
|
May 5, 2007
Haemophilia therapies
Yesim Dargaud, Claude Negrier
Blood Advances
|
October 25, 2018
Emicizumab should be prescribed independent of immune tolerance induction
Sandra Le Quellec, Claude Negrier
Lancet (London, England)
|
August 7, 2007
Coagulation factor concentrates: past, present, and future
Nigel S Key, Claude Negrier
Thrombosis Research
|
September 27, 2008
Intraindividual thrombin generation measurement variability in healthy adults over a one year period
Yesim Dargaud, Stephanie Francillon, Claude Negrier
Blood Reviews
|
June 6, 2019
The central role of thrombin in bleeding disorders
Claude Negrier, Midori Shima, Maureane Hoffman
Blood
|
September 3, 2010
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery
Yesim Dargaud, Anne Lienhart, Claude Negrier
Seminars in Hematology
|
July 17, 2008
Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII
Yesim Dargaud, Jean-Claude Bordet, Anne Lienhart, et al.
Thrombosis and Haemostasis
|
July 22, 2016
Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature
Sandra Le Quellec, Jean-Claude Bordet, Claude Negrier, et al.
Blood
|
May 11, 2011
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
Claude Negrier, Karin Knobe, Andreas Tiede, et al.
Annales De Biologie Clinique
|
September 28, 2010
[Assessment of the interest of using confirmatory test in ELISA with use of high concentration of heparin-induced thrombocytopenia]
Karima Rissoul, Mouhcine Madani, Christophe Nougier, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 61) with videos related to
Sort By:
Page
of 7
Expert Opinion on Biological Therapy
|
May 5, 2007
Haemophilia therapies
Yesim Dargaud, Claude Negrier
Blood Advances
|
October 25, 2018
Emicizumab should be prescribed independent of immune tolerance induction
Sandra Le Quellec, Claude Negrier
Lancet (London, England)
|
August 7, 2007
Coagulation factor concentrates: past, present, and future
Nigel S Key, Claude Negrier
Thrombosis Research
|
September 27, 2008
Intraindividual thrombin generation measurement variability in healthy adults over a one year period
Yesim Dargaud, Stephanie Francillon, Claude Negrier
Blood Reviews
|
June 6, 2019
The central role of thrombin in bleeding disorders
Claude Negrier, Midori Shima, Maureane Hoffman
Blood
|
September 3, 2010
Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery
Yesim Dargaud, Anne Lienhart, Claude Negrier
Seminars in Hematology
|
July 17, 2008
Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII
Yesim Dargaud, Jean-Claude Bordet, Anne Lienhart, et al.
Thrombosis and Haemostasis
|
July 22, 2016
Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature
Sandra Le Quellec, Jean-Claude Bordet, Claude Negrier, et al.
Blood
|
May 11, 2011
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
Claude Negrier, Karin Knobe, Andreas Tiede, et al.
Annales De Biologie Clinique
|
September 28, 2010
[Assessment of the interest of using confirmatory test in ELISA with use of high concentration of heparin-induced thrombocytopenia]
Karima Rissoul, Mouhcine Madani, Christophe Nougier, et al.
Page
of 7